Mutant fragments of OspA and methods and uses relating thereto
The present invention relates to compositions and methods for the prevention and treatment of Borrelia infection. Particularly, the present invention relates to a polypeptide comprising a hybrid C-terminal fragment of an outer surface protein A (OspA), a nucleic acid coding the same, an antibody specifically binding the same, a pharmaceutical composition (particularly for use as a medicament or in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid and/or the antibody, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
1. A polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 27.
2. A pharmaceutical composition comprising the polypeptide according to claim 1 , and optionally a pharmaceutically acceptable carrier or excipient.
3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable excipient comprises L-methionine and/or aluminium hydroxide.
4. A pharmaceutical composition comprising the amino acid sequences of SEQ ID NO: 29, SEQ ID NO: 27 and SEQ ID NO: 33.
5. The polypeptide according to claim 1 for use in a method of treating or protecting against a Borrelia infection, wherein the Borrelia infection is a B. burgdorferi s.s. or B. afzelii infection.
6. The pharmaceutical composition according to claim 2 for use in a method of treating or protecting against a Borrelia infection, wherein the Borrelia infection is a B. burgdorferi s.s. or B. afzelii infection.
7. The pharmaceutical composition according to claim 4 , wherein the pharmaceutical composition is a vaccine.
8. The pharmaceutical composition according to claim 4 , further comprising a pharmaceutically acceptable carrier or excipient.
9. The pharmaceutical composition according to claim 8 , wherein the pharmaceutically acceptable excipient comprises L-methionine and/or aluminium hydroxide.
10. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition is a vaccine.
11. The pharmaceutical composition according to claim 4 for use in a method of treating or protecting against a Borrelia infection, wherein the Borrelia infection is B. burgdorferi s.s. or B. afzelii infection.